XASX
PCK
Market cap11mUSD
Oct 30, Last price
0.08AUD
1D
11.43%
1Q
-18.75%
Jan 2017
-73.51%
IPO
-97.47%
Name
PainChek Ltd
Chart & performance
P/E
—
P/S
4.36
EPS
—
Vol. 1Y
91.81%
Shs. 5Y
13.06%
Rev. 5Y
77.10%
Div Yld LY
—
Div Yld TTM
—
Revenues
4m
+11.29%
Net income
-9m
L+16.46%
CFO
-9m
L+36.79%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PainChek Limited specializes in the creation and commercialization of mobile medical applications designed for individual pain assessment. Their core product, PainChek, employs smartphone and tablet cameras to record video, which is then analyzed in real-time by facial recognition software to detect the presence of pain. This technology is particularly beneficial for patients suffering from dementia. The company, which operates from its headquarters in Sydney, Australia, rebranded as PainChek Limited in January 2018, having previously been known as ePAT Technologies Ltd.
Key people
John Murray
Non-Executive Chairman of the Board · since 2016
Iain McAdam
Chief Financial Officer · since 2021
Philip Daffas
Managing Director, Director · since 2022
Natalie Climo
Company Secretary · since 2024
Adam Davey
Non-Executive Director · since 2014
Ross Harricks
Non-Executive Director · since 2016
Cynthia Payne
Non-Executive Director · since 2022
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||